Related Experiment Video

Updated: Feb 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Tsun Yee Tsang1,2, Wei Wei1,2, Hiroaki Itamochi3

  • 1Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Oncotarget
|December 13, 2017
PubMed

Insights

Clear cell ovarian cancer (CCOC) research identified PRKCI as a key gene. Targeting PRKCI with sodium aurothiomalate (ATM) shows promise for improving CCOC treatment and patient outcomes.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Clear cell ovarian cancer (CCOC) presents unique challenges and a worse prognosis compared to serous ovarian cancer (SOC).
  • The genomic landscape of CCOC remains less understood, hindering the development of targeted therapies.

Purpose of the Study:

  • To conduct an integrated genomic analysis of CCOC to identify potential therapeutic targets.
  • To investigate the role of amplified and overexpressed genes in CCOC progression.

Main Methods:

  • Comparative genomic hybridization and gene expression profiling were used to screen 12 CCOC cell lines and 40 tumors.
  • Pathway analysis was performed on identified amplified and overexpressed genes.

Main Results:

  • 45 amplified and overexpressed genes were identified, with 19 showing cancer-related functions.
  • PRKCI was frequently amplified and overexpressed, promoting CCOC cell proliferation, migration, invasion, and tumor growth in vitro and in vivo.
  • Targeting PRKCI with sodium aurothiomalate (ATM) significantly reduced in vivo tumor growth.

Conclusions:

  • PRKCI is a significant driver in clear cell ovarian cancer.
  • PRKCI inhibition using ATM represents a potential novel therapeutic strategy for CCOC.
Keywords:
PRKCIclear cell ovarian cancergenomicsmicroarraytherapeutic target

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K